Adagio Medical Holdings (ADGM) Q2 2025 earnings summary

Executive summary

• Focused on developing and commercializing ultra-low temperature cryoablation (ULTC) technology for cardiac arrhythmias, with initial emphasis on ventricular tachycardia (VT).

• Achieved over 85% enrollment in the FULCRUM-VT pivotal study for the vCLAS Cryoablation System, targeting completion in the second half of 2025.

• Received FDA Breakthrough Device designation for vCLAS™ Cryoablation System in April 2025.

• Completed a business combination in July 2024, resulting in a new public entity and significant changes to capital structure.

• Implemented a corporate prioritization initiative in February 2025, focusing resources on the FULCRUM-VT clinical trial and product design optimization, and reducing cash burn.

Financial highlights

• No revenue recognized in Q2 2025 due to a pause in commercial activity and inventory buyback in Europe; revenue was $0.3M in Q2 2024.

• Net loss for Q2 2025 was $3.9M, improved from $5.7M in Q2 2024; net loss for the six months ended June 30, 2025 was $11.7M, down from $13.0M in the prior year.

• Cash and cash equivalents were $8.2M as of June 30, 2025, compared to $20.6M at December 31, 2024.

• Operating cash outflows were $11.9M for the six months ended June 30, 2025, compared to $13.7M in the prior year.

• Research and development expenses fell to $2.0M from $2.9M, and SG&A expenses declined to $2.4M from $3.4M year-over-year.

Outlook and guidance

• Current cash is expected to fund operations into Q4 2025; additional capital will be required to complete clinical development and commercialization.

• FULCRUM-VT study enrollment is on track for completion in the second half of 2025, supporting a future FDA premarket approval application.

• Management is pursuing additional equity or debt financing, regulatory approvals, and cost-cutting measures.

• Substantial doubt exists about the ability to continue as a going concern for the next twelve months.